Dashboard PDUFA PDUFA History Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free public preview Track CYTK with free AI briefings, catalyst countdowns, and dilution alerts.

CYTK — CYTOKINETICS INC

FDA catalysts, PDUFA dates with approval probability, drug pipeline, cash runway and insider activity — updated automatically from SEC, FDA and ClinicalTrials.gov data.

$255.3M Cash on Hand

5mo Cash Runway

16.9% Short Interest

💊 Upcoming FDA Decisions

PDUFA Date	Drug	Indication	Type	PoA
2026-11-14	—	adults with symptomatic oHCM to improve functional capacity	sNDA	85%

PoA = estimated probability of approval from published base rates and live data. See the full PDUFA calendar →

🧪 Upcoming Trial Catalysts

2026-09-01 · Phase 2 — Recruiting — AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and
2026-12-31 · Phase 4 — Recruiting — Mavacamten to Aficamten Transition in Patients With Obstructive Hypertrophic Cardiomyopath
2027-03-01 · N/A — Recruiting — HCMR Re-Imaging Study
2027-09-01 · Phase 3 — Recruiting — Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Re
2028-03-01 · Phase 2, Phase 3 — Enrolling — Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten
2030-01-01 · Phase 2, Phase 3 — Recruiting — A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstruc

📊 Drug Pipeline

Drug	Indication	Phase	Status
Aficamten	Hypertrophic Cardiomyopathy (HCM)	PHASE4	RECRUITING
tirasemtiv	Amyotrophic Lateral Sclerosis	PHASE3	COMPLETED
Metoprolol succinate (50 mg, 100 mg, 150	Obstructive Hypertrophic Cardiomyopathy (oHCM)	PHASE3	COMPLETED
Omecamtiv Mecarbil (OM)	Heart Failure	PHASE3	RECRUITING
Aficamten (CK-3773274) (5 mg, 10 mg, 15	Obstructive Hypertrophic Cardiomyopathy (oHCM)	PHASE3	COMPLETED
Aficamten (5 mg, 10 mg, 15 mg, and 20 mg	Obstructive Hypertrophic Cardiomyopathy (oHCM)	PHASE3	COMPLETED
Standard of Care	Heart Failure	PHASE3	COMPLETED
Riluzole	Amyotrophic Lateral Sclerosis	PHASE2	COMPLETED
Reldesemtiv 450 mg	Spinal Muscular Atrophy	PHASE2	COMPLETED
Riluzole 50 MG	Amyotrophic Lateral Sclerosis	PHASE2	COMPLETED

💰 Cash Runway & Dilution Risk

CYTK holds $255.3M in cash and burns about $152.6M/quarter from operations, giving an estimated runway of 5 months. A recent offering filing was detected — dilution watch.

Source: SEC EDGAR XBRL (operating cash flow). Get dilution alerts for CYTK free →

📈 Recent Insider Activity (Form 4)

Date	Insider	Type	Value
2026-07-30	Callos Andrew	Purchase	$1.7M
2026-07-30	Callos Andrew	Sale	$4.7M
2026-07-30	Callos Andrew	Sale	$0
2026-07-23	Malik Fady Ibraham	Purchase	$1.2M
2026-07-23	Malik Fady Ibraham	Sale	$12.4M

📅 Past FDA Decisions & Stock Reactions

Date	Drug	Type	Run-up 30d	Decision 1d	After 5d
2025-12-26	—	NDA	-4.5%	-1.7%	-3.8%

Browse all historical PDUFA outcomes →

Get the full CYTK picture

A free BioRadar account adds AI daily briefings, sentiment tracking, trial enrollment progress, and email alerts for CYTK and 2 more tickers of your choice.

Create Free Account →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z